Reports
Sale
Global Lentiviral Vectors Market Size, Share, Trends, Research: By Components: Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems; By Indications: Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease, Others; By Applications: Gene Therapy, Vaccinology; Regional Analysis; Supplier Landscape; 2024-2032
Global Lentiviral Vectors Market Outlook
The global lentiviral vectors market size was valued at USD 202.81 million in 2023, driven by the increasing prevalence of diabetes and increasing research and development activities across the globe. The market size is anticipated to grow at a CAGR of 15.1% during the forecast period of 2024-2032 to achieve a value of USD 719.05 million by 2032.
Lentiviral Vectors: Introduction
Lentiviral vectors are specialized instruments used in gene therapy and genetic engineering. They originated from a retrovirus family member called lentivirus, a particular class of virus. Given that lentiviruses may infect both proliferating and non-dividing cells, they are beneficial for transferring genetic material into a variety of cell types, including challenging-to-transfect cells like stem cells and neurons.
Lentiviral vectors are lentiviruses that have been modified for the goal of controlled and safe gene delivery. For a variety of purposes, including gene therapy, genetic research, and experimental studies, they can be used to introduce genes or genetic material into target cells.
Global Lentiviral Vectors Market Analysis
The global market for lentiviral vectors is witnessing significant growth in the market and is anticipated to keep growing in the coming years as well. Factors such as the increasing research and development activities by key players and a significant shift towards patient centric healthcare are directly driving the lentiviral vectors market growth. Key players across the globe are now taking initiative towards collaborating with each other to produce more effective treatments of genetic disorders caused by single-gene mutations, such as severe combined immunodeficiency (SCID), hemophilia, muscular dystrophy, and certain types of blindness. The success of recent clinical trials using lentiviral vectors for certain genetic disorders, as it provides reliable techniques to deliver therapeutic genes into cells, has further fueled the demand for lentiviral vectors in the global market.
In response to the growing demand for starting materials for use in cell therapy, a leading cell therapy company based in the United States is creating allogeneic genetically modified CAR-NK cells using umbilical cord blood and has announced a collaboration agreement with California-based regenerative therapeutics company StemCyte. This collaboration is expected to further propel market growth as it is expected to cater as a catalyst for advancements and growth in the market.
Global Lentiviral Vectors Market Segmentations
Market Breakup by Components
- Lentiviral Promoter
- Lentiviral Fusion Tags
- Lentivirus Packaging Systems
Market Breakup by Indications
- Cancer
- Genetic Disorders
- Infectious Diseases
- Veterinary Disease
- Other
Market Breakup by Applications
- Gene Therapy
- Vaccinology
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Lentiviral Vectors Market Overview
The increasing geriatric population worldwide is a major factor driving the market growth. The increasing prevalence of chronic diseases, such as diabetes, are also contributing to the market growth due to the need for gene therapy improving glycemic control and reducing the need for insulin therapy.
According to WHO, diabetes was the cause of death of over 1.5 million people aged below 70 years of age in 2020. Lentiviral vectors are used to cure a wide range of disorders that are genetically influenced, such as cancer immunotherapy, neurodegenerative disease, hematopoietic disorders, inherited metabolic disorders, HIV/AIDS research, vaccine development, and rare diseases.
Lentiviral vectors act as prominent tools to study gene function, expression, and regulation. The increased demand for such tools with increasing awareness about the potential of lentiviral vectors is directly contributing to the rising global lentiviral vectors market share.
Additionally, due to the strong ability of lentiviral vectors in used in developing personalized treatments for patients by targeting specific genetic mutations accounting for diseases is also driving the market growth. The continuous ongoing research and development activities on lentiviral vectors are being explored for innovative therapeutic approaches, including cancer immunotherapy, neurodegenerative disease treatment, and regenerative medicine which is further propelling the market growth.
Lentiviral Vectors Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Cobra Biologics Limited
- Sirion-Biotech GmbH
- Merck KGaA
- FinVector Oy
- Oxford Biomedica
- OriGene Technologies, Inc.
- Sino Biological Inc.
- Cell Biolabs, Inc.
- Batavia Biosciences B.V.
- Lonza
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Components |
|
| Breakup by Indications |
|
| Breakup by Applications |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Lentiviral Vectors Market Overview
3.1 Global Lentiviral Vectors Market Historical Value (2017-2023)
3.2 Global Lentiviral Vectors Market Forecast Value (2024-2032)
4 Global Lentiviral Vectors Market Landscape
4.1 Global Lentiviral Vectors: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Lentiviral Vectors: Product Landscape
4.2.1 Analysis by Components
4.2.2 Analysis by Technology
4.2.3 Analysis by Indication
5 Global Lentiviral Vectors Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Lentiviral Vectors Market Segmentation
6.1 Global Lentiviral Vectors Market by Components
6.1.1 Market Overview
6.1.2 Lentiviral Promoter
6.1.3 Lentiviral Fusion Tags
6.1.4 Lentivirus Packaging Systems
6.2 Global Lentiviral Vectors Market by Indications
6.2.1 Market Overview
6.2.2 Cancer
6.2.3 Genetic Disorders
6.2.4 Infectious Diseases
6.2.5 Veterinary Disease
6.2.6 Others
6.3 Global Lentiviral Vectors Market by Applications
6.3.1 Market Overview
6.3.2 Gene Therapy
6.3.3 Vaccinology
6.4 Global Lentiviral Vectors Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Lentiviral Vectors Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Lentiviral Vectors Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Lentiviral Vectors Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Lentiviral Vectors Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Lentiviral Vectors Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Cobra Biologics Limited
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Sirion-Biotech GmbH
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Merck KGaA
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 FinVector Oy
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Oxford Biomedica
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 OriGene Technologies, Inc.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Sino Biological Inc.
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Cell Biolabs, Inc.
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Batavia Biosciences B.V.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Lonza
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 202.81 million in 2023, driven by the increasing demand for precision and personalized treatment across the globe.
The market is anticipated to grow at a CAGR of 15.1% during the forecast period of 2024-2032, likely to reach a market value of USD 719.05 million by 2032.
The increasing prevalence of chronic disease, such as diabetes, is among the major factors driving the market growth. The significant shift towards personalized and precision medicine are also among the major factors driving the market growth.
The increasing number of research and development activities by key players is the major trend influencing the market growth.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.
The components include lentiviral promoter, lentiviral fusion tags, and lentivirus packaging systems.
Indications include cancer, genetic disorders, infectious diseases, and veterinary disease, among others.
They find wide applications in gene therapy and vaccinology.
Key players involved in the market are Cobra Biologics Limited, Sirion-Biotech GmbH, Merck KGaA, FinVector Oy, Oxford Biomedica, OriGene Technologies, Inc., Sino Biological Inc., Cell Biolabs, Inc., Batavia Biosciences B.V., and Lonza.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER